Aripiprazole transdermal - Aequus Pharmaceuticals

Drug Profile

Aripiprazole transdermal - Aequus Pharmaceuticals

Alternative Names: AQS-1301; Transdermal aripiprazole - Aequus

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aequus Pharmaceuticals
  • Developer Aequus Pharmaceuticals; Corium International
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor partial agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autistic disorder; Bipolar disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 16 Nov 2017 Aequus Pharmaceuticals has patent protection for Aripiprazole transdermal in Europe, USA, Russia, Mexico, Canada and Australia
  • 10 Oct 2017 Aequus Pharmaceuticals has patent protection for aripiprazole transdermal for psychiatric disorders in China
  • 10 Oct 2017 Aequus Pharmaceuticals has patent protection for aripiprazole transdermal in USA and Canada before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top